Women who intentionally lost five per cent or more of their body weight had 29 per cent lower risk of developing endometrial cancer during the study.
Postmenopausal women who intentionally lost weight over the course of three years had a much lower risk of endometrial cancer up to 11 years later compared to women whose weight didn’t change, a US study finds.
Overall, women who intentionally lost five per cent or more of their body weight had 29 per cent lower risk of developing endometrial cancer during the study period, and the effect was most pronounced for obese women, whose risk dropped by 66 per cent with weight loss.
“We decided to do the study because we realised that, although obesity increases the risk of endometrial cancer, research couldn’t say if intentional weight loss, especially among older persons, could reduce that risk,” said lead author Juhua Luo, School of Public Health at Indiana University in Bloomington.
This story is from the March 16, 2017 edition of Express Pharma.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the March 16, 2017 edition of Express Pharma.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
ACG covers every facet of the pharma process, all under one roof and seamlessly interconnected
ACG Inspection's Life Sciences Cloud will be making its India debut at the CPhI India- PMec India 2024 show. Udit Singh, CEO, ACG Inspection spoke to Viveka Roychowdhury on its USPs, highlighting its modular nature, the zero cost of transition from existing systems, and the advantage of ACG's long term partnerships with global standard setting organisations like GS1 which allow its platforms to deliver regulatory compliance deliverables in advance
We, at OmniActive, invest over 10 per cent of the total outlay into R&D
Sanjaya Mariwala, Executive Chairman and MD, OmniActive Health Technologies shares insights into the company's significant investments in R&D, advanced testing capabilities, and strategies for optimising bioactive ingredients. He also discusses the impact of regulatory changes, quality assurance, and consumer education in the evolving nutraceutical landscape, in an interview with Viveka Roychowdhury
Save coating time, boost production efficiency
Instacoat 4G unique formulation includes an optimal ratio of polymer, plasticizer, and pigments, ensuring a smooth, uniform coating while significantly reducing preparation and process time
Pharma companies can optimise R&D budgets using advanced technologies
Pharma companies can optimise their R&D budgets to maximise innovation and deliver high-value therapies by using combination of new technologies to enhance innovation, feed the drug-development pipeline and speed to market.
The wide-ranging health benefits of Pycnogenol for women of all ages
Dr Franziska Weichmann, Manager of Scientific Communications and Product Development at Horphag Research, highlights benefits of Pycnogenol, a French maritime pine bark extract, offering women across all life stages a natural way to manage the physical and emotional challenges tied to hormonal changes
Indian pharma industry: Urgent need for action in the manufacturing sector
Dr Ajay Babu Pazhayattil, President of cGMPWorld, offers invaluable insights from FDA Form 483 observations issued to Indian pharma facilities, shedding light on the industry's critical challenges today. His analysis provides immediate and practical plans to minimise regulatory compliance risks. These measures will help reinforce the Indian industry's commitment to supplying the much-needed lifesaving drug products for the regulated US market
Nutraceutical M&As: How strategic mergers are shaping the health and wellness market
The nutraceutical industry has seen a surge in M&A activity over the past three years as companies pursue strategic acquisitions to strengthen market positions, diversify offerings, and drive innovation. Sudhindran N, GM - Corporate Affairs, Nutrify Today explores key trends, motivations, notable deals, and future growth prospects shaping the industry
Rising research costs, complex drug systems, stringent regulations, and global pressures pose major threats to pharma R&D
According to one of the published reports, the pharma industry invested about $83 billion in R&D in 2019, which is about 10 times the research and development (R&D) spent per year in the 1980s, after adjusting for the effects of inflation.
Harnessing data analytics to propel drug discovery and development in 2025
As the pharma landscape evolves, data analytics will be at the forefront of drug discovery and development, transforming traditional methods. By leveraging data-driven insights, companies can expedite R&D, optimise clinical trials, and personalise treatments, bringing life-saving therapies to market more efficiently, explains Biju Davis, SVP, Engineering, Model N
Strengthening our presence within APAC through increased penetration is a key focus
Aanchal Tomar, Executive Director, Asia Pacific, Lonza Capsules Health Ingredients speaks about Lonza Capsules Health Ingredients’ strategic growth, challenges, and sustainability initiatives in the APAC market, showcasing their innovative capsule solutions and health ingredients that cater to the region's diverse pharmaceutical and nutraceutical needs, in an interview with Express Pharma
